来那度胺联合地塞米松治疗复发难治性轻链淀粉样变性的疗效及安全性

发布时间：2018-03-07 07:11

本文选题：轻链淀粉样变性　切入点：来那度胺　出处：《肾脏病与透析肾移植杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的:观察来那度胺联合地塞米松(LD)治疗复发难治性轻链淀粉样变性(AL型)的临床疗效及安全性。方法:收集2012年12月至2015年11月在南京总医院国家肾脏疾病临床医学研究中心接受LD治疗的复发难治性AL淀粉样变性患者的临床资料。回顾性分析血液学、器官反应情况及不良反应。结果:共10例患者纳入研究,其中男性7例、女性3例,中位年龄为64.5(56.8,68.8)岁。7例患者纳入疗效分析,3例患者获得血液学应,其中1例获得完全缓解。7例患者均未获得肾脏反应,2例获得心脏反应。所有患者均存活,无血液学进展,2例心脏进展,1例进入终末期肾病。无一例发生血液学进展。3/4级不良反应发生率30%。结论:LD方案作为复发难治性AL淀粉样变性患者的挽救治疗有一定的疗效且安全性较高,严重不良反应发生率较低。
[Abstract]:Objective: to observe the clinical efficacy and safety of renalidomide combined with dexamethasone (LDX) in the treatment of refractory refractory amyloidosis (AL). Methods: from December 2012 to November 2015, the National Renal Disease of Nanjing General Hospital was collected. Clinical data of patients with recurrent refractory AL amyloidosis treated with LD. Retrospective analysis of hematology. Results: a total of 10 patients were included in the study, including 7 males and 3 females, with a median age of 64.5 / 56.8 / 68.8). One of the 7 patients with complete remission had no renal response and 2 had cardiac response. All the patients survived. No hematological progress was found in 2 patients with cardiac progression and 1 patient entered end-stage nephropathy. No hematological progression. 3 / 4 grade adverse reaction rate was 30%. Conclusion the fraction LD regimen is a salvage therapy for refractory AL amyloidosis. Has high efficacy and safety. The incidence of severe adverse reactions was lower.
【作者单位】：南京军区南京总医院肾脏科国家肾脏疾病临床医学研究中心全军肾脏病研究所;
【基金】：国家科技支撑计划项目课题(2015BAI09B05,2015BAI12B02) 江苏省青年医学人才计划(QNRC2016895) 国家“精准医学”重点研发计划项目(2016YFC0904100)
【分类号】：R597.2

【相似文献】